AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...

The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...

Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

Oracle stock fell Tuesday as investors digested fiscal second quarter earnings results that missed estimates. Oracle touted a ...

Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's ...

Treatment with tavapadon led to a statistically significant improvement in motor function compared with placebo. Topline results were announced from a phase 3 trial evaluating tavapadon, a selective ...

“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

Recent headlines in health news spotlight several pharmaceutical developments: AbbVie's Parkinson's drug shows promise in ...

US pharma major AbbVie announced positive top-line results from its pivotal Phase III TEMPO-2 trial evaluating ...

The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.

Researchers identified 13 proteins that predicted how quickly or slowly a person's brain aged. (Nature Aging) Midlife anxiety ...